NanoBio, the Ann Arbor, MI-based company developing nanotech formulations of drugs and vaccines, said today it has been awarded a $1.5 million federal research grant along with the University of Michigan to study how to prevent burn wounds on the battlefield from getting dangerously infected. The grant, from the U.S. Department of Defense, will be used for experiments to pave the way for clinical trials of NB-201, a topical anti-infective treatment designed to reduce the severity of infections in burn wounds and inflammation after a burn injury, the company said in a statement.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
